169 related articles for article (PubMed ID: 23724854)
1. Observational case series on a group of psoriasis patients who failed to respond to any TNF blockers.
Viguier M; Livideanu C; Beylot-Barry M; Richard MA; Paul C; Bachelez H; Aubin F;
J Dermatolog Treat; 2014 Feb; 25(1):75-7. PubMed ID: 23724854
[TBL] [Abstract][Full Text] [Related]
2. Clinical predictors of non-response to any tumor necrosis factor (TNF) blockers: a retrospective study.
Di Lernia V; Ricci C; Lallas A; Ficarelli E
J Dermatolog Treat; 2014 Feb; 25(1):73-4. PubMed ID: 23621374
[TBL] [Abstract][Full Text] [Related]
3. Management of severe psoriasis with TNF antagonists. Adalimumab, etanercept and infliximab.
Mössner R; Reich K
Curr Probl Dermatol; 2009; 38():107-136. PubMed ID: 19710553
[TBL] [Abstract][Full Text] [Related]
4. Anti-TNF agents and nail psoriasis: a single-center, retrospective, comparative study.
Kyriakou A; Patsatsi A; Sotiriadis D
J Dermatolog Treat; 2013 Jun; 24(3):162-8. PubMed ID: 22136334
[TBL] [Abstract][Full Text] [Related]
5. Antinuclear antibodies associate with loss of response to antitumour necrosis factor-alpha therapy in psoriasis: a retrospective, observational study.
Pink AE; Fonia A; Allen MH; Smith CH; Barker JN
Br J Dermatol; 2010 Apr; 162(4):780-5. PubMed ID: 19863499
[TBL] [Abstract][Full Text] [Related]
6. Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris.
Gniadecki R; Kragballe K; Dam TN; Skov L
Br J Dermatol; 2011 May; 164(5):1091-6. PubMed ID: 21219290
[TBL] [Abstract][Full Text] [Related]
7. Survival rate of antitumour necrosis factor-α treatments for psoriasis in routine dermatological practice: a multicentre observational study.
Esposito M; Gisondi P; Cassano N; Ferrucci G; Del Giglio M; Loconsole F; Giunta A; Vena GA; Chimenti S; Girolomoni G
Br J Dermatol; 2013 Sep; 169(3):666-72. PubMed ID: 23647206
[TBL] [Abstract][Full Text] [Related]
8. Baseline anti-dsDNA concentrations and previous treatments predict response to Adalimumab and Etanercept: a retrospective investigation of 146 psoriasis patients.
Hoffmann JH; Knoop C; Enk AH; Hadaschik EN
J Dermatol Sci; 2014 Dec; 76(3):180-5. PubMed ID: 25306295
[TBL] [Abstract][Full Text] [Related]
9. Weight gain and tumour necrosis factor-alpha inhibitors in patients with psoriasis.
Tan E; Baker C; Foley P
Australas J Dermatol; 2013 Nov; 54(4):259-63. PubMed ID: 24164178
[TBL] [Abstract][Full Text] [Related]
10. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis.
Collamer AN; Battafarano DF
Semin Arthritis Rheum; 2010 Dec; 40(3):233-40. PubMed ID: 20580412
[TBL] [Abstract][Full Text] [Related]
11. Antidrug antibodies in psoriasis: a systematic review.
Hsu L; Snodgrass BT; Armstrong AW
Br J Dermatol; 2014 Feb; 170(2):261-73. PubMed ID: 24117166
[TBL] [Abstract][Full Text] [Related]
12. Adalimumab for psoriasis patients who are non-responders to etanercept: open-label prospective evaluation.
Martyn-Simmons CL; Green L; Ash G; Groves RW; Smith CH; Barker JN
J Eur Acad Dermatol Venereol; 2009 Dec; 23(12):1394-7. PubMed ID: 19573024
[TBL] [Abstract][Full Text] [Related]
13. The role of Fcγ receptor polymorphisms in the response to anti–tumor necrosis factor therapy in psoriasis A pharmacogenetic study.
Julià M; Guilabert A; Lozano F; Suarez-Casasús B; Moreno N; Carrascosa JM; Ferrándiz C; Pedrosa E; Alsina-Gibert M; Mascaró JM
JAMA Dermatol; 2013 Sep; 149(9):1033-9. PubMed ID: 24048425
[TBL] [Abstract][Full Text] [Related]
14. Treatment patterns in the first year after initiating tumor necrosis factor blockers in real-world settings.
Bonafede M; Fox KM; Watson C; Princic N; Gandra SR
Adv Ther; 2012 Aug; 29(8):664-74. PubMed ID: 22886712
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of subcutaneous anti-tumor necrosis factor-alpha agents, etanercept and adalimumab, in elderly patients affected by psoriasis and psoriatic arthritis: an observational long-term study.
Esposito M; Giunta A; Mazzotta A; Zangrilli A; Babino G; Bavetta M; Perricone R; Chimenti S; Chimenti MS
Dermatology; 2012; 225(4):312-9. PubMed ID: 23295383
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of systemic treatments for moderate to severe plaque psoriasis: systematic review and meta-analysis.
Bansback N; Sizto S; Sun H; Feldman S; Willian MK; Anis A
Dermatology; 2009; 219(3):209-18. PubMed ID: 19657180
[TBL] [Abstract][Full Text] [Related]
17. Clinical experience of QuantiFERON(®) -TB Gold testing in patients with psoriasis treated with tumour necrosis factor blockers in Taiwan.
Chiu HY; Hsueh PR; Tsai TF
Br J Dermatol; 2011 Mar; 164(3):553-9. PubMed ID: 21083541
[TBL] [Abstract][Full Text] [Related]
18. Switching to adalimumab in patients with moderate to severe psoriasis who have failed on etanercept: a retrospective case cohort study.
Woolf RT; Smith CH; Robertson K; Barker JN
Br J Dermatol; 2010 Oct; 163(4):889-92. PubMed ID: 20854408
[No Abstract] [Full Text] [Related]
19. [Efficacy of TNF-alpha antagonists for plaque-type psoriasis: a systematic review and graphical presentation].
Levy-Roy A; Porcher R; de Fonclare AL; Morel P; Dupuy A
Ann Dermatol Venereol; 2009 Apr; 136(4):315-22. PubMed ID: 19361697
[TBL] [Abstract][Full Text] [Related]
20. Tumor necrosis factor inhibitors in psoriasis: an update.
Kerdel FA; Strober BE
Semin Cutan Med Surg; 2014 Mar; 33(2 Suppl 2):S31-6. PubMed ID: 24979543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
